FTH +87%, CRMT +64% Soar on EPS Estimate Revisions; LILA, LILAK, RYTM Rally
Faeth Therapeutics (FTH) surged 87.4% after its next-year EPS growth estimate was raised to 93.7% on June 16. Americas Car Mart (CRMT) gained 63.7% on a 101.7% EPS growth revision, while Liberty Latin America (LILA/LILAK) jumped over 34% on massive upward estimate changes of 131.8 and 1,799.9 percentage points respectively. Rhythm Pharmaceuticals (RYTM) added 21.7% on a 76.7% EPS growth estimate. All moves occurred without earnings-related news, driven purely by analyst revisions and sector momentum.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FTH | Healthcare | 2026-06-16 | N/A | +87.4% |
| CRMT | Consumer Cyclical | 2026-06-16 | N/A | +63.7% |
| LILA | Communication Services | 2026-06-18 | +131.8pp | +35.6% |
| LILAK | Communication Services | 2026-06-18 | +1799.9pp | +34.7% |
| RYTM | Healthcare | 2026-06-15 | N/A | +21.7% |
Why did FTH stock jump in June 2026?
FTH jumped 87.4% (from $14.53 to $27.23) after analysts raised its next-year EPS growth estimate to 93.7% on June 16.
The healthcare sector saw broad momentum for speculative biotech names, and Faeth's heavy revenue growth outlook attracted buyers. No earnings news was released, but the upward revision alone triggered a re-rating as the market bet on future profitability.
FTH EPS revision history → · Screener snapshot from 2026-06-16 →
FAQ: FTH
Why did FTH stock jump in June 2026?
FTH surged 87.4% after its next-year EPS growth estimate was raised to 93.7% on June 16, signaling strong expected earnings turnaround.
Is FTH a buy after the rally?
The 93.7% EPS growth estimate implies high forward profitability, but investors should monitor if fundamentals match the revised projection.
What is FTH's EPS growth estimate?
Faeth Therapeutics' next-year EPS growth estimate stands at 93.7% as of the revision on June 16.
Why did CRMT stock jump in June 2026?
CRMT jumped 63.7% (from $2.34 to $3.83) after analysts raised its next-year EPS growth estimate to 101.7% on June 16.
The consumer cyclical sector attracted value-seeking investors betting on a turnaround, and the low share price amplified the move. The revision alone, without earnings news, drove the rally as the market priced in a stronger earnings recovery.
CRMT EPS revision history → · Screener snapshot from 2026-06-16 →
FAQ: CRMT
Why did CRMT stock jump in June 2026?
CRMT gained 63.7% after its next-year EPS growth estimate was raised to 101.7% on June 16, reflecting optimism about earnings recovery.
Is CRMT a buy after the rally?
The 101.7% EPS growth estimate suggests a strong turnaround, but the stock remains speculative given its low price and lack of news.
What caused CRMT's surge?
The surge was driven by an upward EPS estimate revision to 101.7% next-year growth, with no other earnings-related catalysts.
Why did LILA stock jump in June 2026?
LILA jumped 35.6% (from $4.80 to $6.51) after analysts revised its next-year EPS growth estimate from 208.4% to 340.3% on June 18.
The 131.8 percentage point upward revision reflected accelerating earnings expectations for Liberty Latin America. Communication services stocks rallied on Latin American recovery hopes, and the screener caught the move before the broader market fully priced it in.
LILA EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILA
Why did LILA stock jump in June 2026?
LILA rose 35.6% after analysts raised its next-year EPS growth estimate from 208.4% to 340.3% on June 18.
What caused LILA's surge?
The surge was caused by a 131.8 percentage point upward EPS estimate revision, alongside sector momentum in Latin American telecoms.
What is LILA's EPS growth estimate?
LILA's next-year EPS growth estimate is 340.3%, up from 208.4% after the June 18 revision.
Why did LILAK stock jump in June 2026?
LILAK jumped 34.7% (from $4.79 to $6.45) after analysts revised its next-year EPS growth estimate from 413.6% to 2213.6% on June 18.
The massive 1,799.9 percentage point increase signaled an extreme earnings turnaround expectation. Both Liberty Latin America share classes moved in tandem, reflecting a sector-wide reassessment of the company's prospects.
LILAK EPS revision history → · Screener snapshot from 2026-06-18 →
FAQ: LILAK
Why did LILAK stock jump in June 2026?
LILAK surged 34.7% after analysts raised its next-year EPS growth estimate from 413.6% to 2,213.6% on June 18.
What caused LILAK's surge?
The move was driven by a 1,799.9 percentage point upward EPS estimate revision, the largest among the cohort.
What is LILAK's EPS growth estimate?
LILAK's next-year EPS growth estimate is 2,213.6% after the June 18 revision, up from 413.6%.
Why did RYTM stock jump in June 2026?
RYTM jumped 21.7% (from $89.70 to $109.15) after analysts raised its next-year EPS growth estimate to 76.7% on June 15.
The healthcare stock benefited from a strong pipeline and clinical progress expectations. The upward revision reinforced confidence in Rhythm Pharmaceuticals' growth trajectory, leading to a sustained rally even without specific news.
RYTM EPS revision history → · Screener snapshot from 2026-06-15 →
FAQ: RYTM
Why did RYTM stock jump in June 2026?
RYTM rose 21.7% after analysts raised its next-year EPS growth estimate to 76.7% on June 15.
Is RYTM a buy after the rally?
The 76.7% EPS growth estimate supports the rally, but investors should weigh pipeline risks against the revised outlook.
What caused RYTM's surge?
The surge was triggered by an upward EPS estimate revision to 76.7% next-year growth, signaling improving fundamentals.
These EPS revision-driven rallies highlight a market rewarding earnings turnarounds, especially in healthcare and consumer cyclicals. The momentum suggests continued appetite for high-growth names with improving fundamentals.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →